Projects / Programmes
Prenatal screening tests for complications and chromosomopaties
| Code |
Science |
Field |
Subfield |
| 3.05.00 |
Medical sciences |
Human reproduction |
|
| Code |
Science |
Field |
| B570 |
Biomedical sciences |
Obstetrics, gynaecology, andrology, reproduction, sexuality |
prenatal screening tests, genetics, Down's syndrome, ultrasound, nuchal translucency, biochemical markers, complications in pregnancy, in vitro fertilisation-embrio transfer
Researchers (25)
Organisations (1)
Abstract
With screening tests now in use we are not able to predict all pregnancy complications or find all chromosomopaties, the best known of which is Down's syndrome. Pregnant women, after a positive result of a screening test, are subjected to invasive tests and psychological stress. A very special problem are false negative results of screening tests.To decrease false positive and false negative results we intend to introduce new markers. So, for calculations of risk not only maternal age and nuchal translucency measurement are used, but also biochemical markers as free beta human chorionic gonadotrophin, PAPP-A and others. These could help us also predict obstetrical complications later in pregnancy, which might be of use for preventing or decreasing the negative effect of complications. The values might be different in pregnant women after in vitro fertilisation - embrio transfer procedure, which is important when interpreting the results. Pregnant women, after informed consent, in first and early second trimester will be included in the study, approved by the Committee for medical ethics, nuchal translucency measured and biochemical markers determined. Data on mode of conception, pregnancy and the newborn will be collected. We will pay special attention to psychological wellbeing of pregnant women.
